South Korean Samsung Group’s biopharmaceutical business is being reorganized into two separate tracks: contract development ...

SEOUL ― South Korean drugmaker Samsung BioLogics said on Thursday it plans to separate the company into contract manufacturing and development companies to help allay customer concerns about conflicts ...

Seoul: Samsung Biologics, a biotech arm of South Korea's Samsung Group, said on Thursday it plans to spin off its biosimilar ...

In a bid to allay conflict-of-interest concerns, Korean manufacturing giant Samsung Biologics is decoupling from its ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Samsung Biologics Co., the biotech arm of South Korea's Samsung Group, announced Thursday that it plans to spin off its ...

SEOUL, May 23 (Yonhap) -- The following are the top headlines in major South Korean newspapers on May 23.